Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sean Lee CFA
HC
Sean Lee CFA
H.C. Wainwright
Wall Street Analyst
★★★★☆
#597
on 13Foresight · ranked by our own returns
58%
Success Rate
+18.9%
Average Return
7 of 12 calls profitable · +10.5% vs benchmark
📈 Across the calls we could measure, roughly 58% of Sean Lee CFA's ratings turned a profit when each position was held for 1 year — averaging +18.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

59 Buy 4 Hold 0 Sell
Sean's Stock Coverage 16 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
SENS
Senseonics Holdings
 Jun 08, 2026 BUY Buy
+124.8% avg upside
13 analysts
$14.00
107.78% Upside
 ·
KZIA
Kazia Therapeutics
 Jun 04, 2026 BUY Strong Buy
+68.4% avg upside
6 analysts
$18.00
29.92% Upside
 ·
DWTX
Dogwood Therapeutics
 May 19, 2026 BUY Strong Buy
+771.0% avg upside
2 analysts
$12.00
674.22% Upside
 ·
CRVS
Corvus Pharmaceuticals
 May 15, 2026 BUY Strong Buy
+114.5% avg upside
14 analysts
$27.00
126.69% Upside
 -2.5%
CTSO
Cytosorbents
 May 14, 2026 HOLD Strong Buy
+2611.9% avg upside
13 analysts
$0.75
71.07% Upside
 +0.0%
MYO
Myomo
 May 08, 2026 BUY Strong Buy
+464.7% avg upside
9 analysts
$5.00
290.57% Upside
 +4.8%
ATEC
Alphatec Holdings
 May 07, 2026 BUY Strong Buy
+112.9% avg upside
22 analysts
$24.00
172.52% Upside
 +4.4%
AKTX
Akari Therapeutics
 Apr 21, 2026 BUY Strong Buy
+957.3% avg upside
7 analysts
$27.00
146.84% Upside
 +149.2%
NVAX
Novavax
 Apr 21, 2026 BUY Buy
+154.1% avg upside
20 analysts
$16.00
75.32% Upside
 +4.6%
PSTV
Plus Therapeutics
 Mar 16, 2026 BUY Strong Buy
+688.7% avg upside
11 analysts
$25.00
495.33% Upside
 -16.6%
CASIF
CASI Pharmaceuticals
 Dec 09, 2025 BUY Strong Buy
+14376.2% avg upside
5 analysts
$4.00
2185.65% Upside
 ·
VSTM
Verastem
 Nov 05, 2025 BUY Strong Buy
+260.2% avg upside
23 analysts
$14.00
239.87% Upside
 -51.0%
FR:OSE
OSE Immunotherapeutics SA
 May 07, 2025 BUY Strong Buy
+229.3% avg upside
4 analysts
$14.00
300.84% Upside
 ·
IPHA
Innate Pharma
 Apr 24, 2025 BUY Strong Buy
+261.8% avg upside
10 analysts
$11.00
507.73% Upside
 -29.8%
MNPR
Monopar Therapeutics Inc
 Apr 01, 2025 BUY Strong Buy
+45.9% avg upside
18 analysts
$40.00
40.70% Downside
 +65.7%
THMO
ThermoGenesis Holdings
 Mar 21, 2025 HOLD Buy
+7499899.9% avg upside
4 analysts
 — ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sean Lee CFA — Frequently Asked Questions
How accurate are Sean Lee CFA's stock ratings?
Based on the calls 13Foresight could measure, about 58% of Sean's ratings were profitable over a one-year hold, with an average return of +18.9% per rating, or +10.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Sean ranked on 13Foresight?
Sean Lee CFA is currently ranked #597 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sean cover?
Sean most recently has ratings on SENS, KZIA, DWTX, CRVS, CTSO, MYO, ATEC, AKTX, NVAX, PSTV, CASIF, VSTM and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.